1. Scripps Research Institute Scientists Identify First Potentially Effective Therapy for Human Prion Disease   
  2. Probe from SRIMSC Enters Phase II/III Clinical trials.   
  3. The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!   
  4. Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science   
  5. NIH Common Fund researchers uncover structure of important target for drug design   
  6. NIH Research Matters: Designing New Diabetes Drugs   
  7. Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]    
  8. Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand   
  9. Scripps Research and MIT scientists discover class of potent anti-cancer compounds    
  10. MLP Probe Project Leads to First in Human Studies    
  11. Business Wire:   Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis   
  12. Nature:   Quantitative reactivity profiling predicts functional cysteines in proteomes.

  13. Nature:   Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5.
  14. Discovery and optimization of chemical probes to define important molecular signals in medicine.
  15. Nature Reviews Drug Discovery article:   Chemical modulators of S1P receptors as barrier-oriented therapeutic molecules.
  16. Nature Chemical Biology article: S1P1 signaling just keeps going and going and going…
  17. Nature Biotechnology article:   Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.
Home » Cores
Assay Development

The overarching goal for Assay Development focuses on the timely delivery of robust and well validated assays to uHTS.  Over the last 12 months, the Assay Development group has worked on more than 50 assays from 29 PI’s outside of the MLSCN Center of which 13 were also outside of the Scripps Research Institute. 23 assays were successfully transferred to uHTS.  The breadth of our assay development production competency and the extent of our Outreach efforts to other institutions on behalf of MLSCN is demonstrated by the range of target classes and assay platforms shown below:

Assay Formats

Screening Capabilities

Biologicial Expertise

  • Fluorescence Intensity
  • Fluorescence Polarization
  • TRF
  • FRET
  • Luminescence
  • Absorbance
  • AlphaScreen
  • FITC
  • GFP
  • Cell Imaging
  • Fluorescent Microscopy
  • GPCRs
  • Receptor-ligand interaction
  • Protein-protein interactions
  • Enzyme Assays
  • Ion Channels
  • Reporter Assays
  • Viability Assays
  • Protein Translocation

Visit the Rosen Laboratory.

 
Copyright (c) 2008-2011 TSRI.